바이오테크놀러지용 AI 시장 : 기술별(Drug Discovery 및 개발, 유전체학 및 유전자 편집, 정밀의료, 바이오프로세스 및 제조, 진단 및 영상), 도입 형태별(클라우드 기반, 온프레미스), 용도별 - 세계 예측(-2036년)

AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-Based, On-Premise), End-Use, and Geography - Global Forecast to 2036

According to the research report titled, 'AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-Based, On-Premise), End-Use, and Geography - Global Forecast to 2036,' the global AI in biotechnology market is expected to reach approximately USD 46.1 billion by 2036 from USD 6.41 billion in 2026, at a CAGR of 21.8% during the forecast period (2026-2036). The report provides an in-depth analysis of the global AI in biotechnology market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The major factors driving the growth of the AI in biotechnology market include the accelerating convergence of computational biology and biological sciences and the breakthrough innovations in drug discovery and personalized treatment protocols. Additionally, the rapid expansion of genomic datasets, increasing need for high-throughput screening in complex disease environments, and integration of advanced AI algorithms are expected to create significant growth opportunities for players operating in the AI in biotechnology market.

Market Segmentation

The AI in biotechnology market is segmented by technology (drug discovery & development, genomics & gene editing, precision medicine, bioprocessing & manufacturing, diagnostics & imaging), deployment (cloud-based, on-premise), end-use, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Technology

By technology, the drug discovery & development segment holds the largest market share in 2026, primarily attributed to its critical role in supporting small molecule design, target identification, and accelerated clinical candidate optimization. AI-powered drug discovery platforms provide substantial competitive advantages in biological research and clinical translation. However, the genomics & gene editing segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of AI for genetic sequence analysis and CRISPR-based therapeutic development. The ability to deliver integrated solutions with proven clinical validation makes advanced genomics AI platforms highly attractive for biotechnology companies.

Based on Deployment

By deployment, the cloud-based segment holds the largest market share in 2026, owing to its scalability and ability to handle massive biological datasets with collaborative research workflows. Cloud-based AI platforms provide superior accessibility for distributed research teams and institutions. The on-premise segment is expected to witness significant growth during the forecast period, driven by the need for data security compliance and the requirement for real-time processing in specialized laboratory environments. Organizations with stringent intellectual property and regulatory requirements continue to favor on-premise deployment models for sensitive research applications.

Based on End-Use

By end-use, the pharmaceutical companies segment holds the largest share of the overall market in 2026, due to their substantial investments in computational biology infrastructure and the need for accelerated drug development pipelines. Pharmaceutical organizations represent the primary adopters of AI biotechnology solutions. The biotechnology companies segment is expected to grow at a significant CAGR during the forecast period, driven by the increasing adoption of AI for research acceleration and the development of specialized AI-powered therapeutic platforms. Academic research institutions and contract research organizations represent emerging segments with growing adoption of advanced AI biotechnology tools.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global AI in biotechnology market with the largest market share, primarily attributed to substantial investments in computational biology infrastructure and the concentration of leading pharmaceutical innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by expanding biotech research capabilities and government initiatives promoting AI-driven healthcare innovation in China, India, and Singapore. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing biotechnology research infrastructure and increasing adoption of advanced AI technologies.

Key Players

The key players operating in the global AI in biotechnology market are IBM Corporation, Microsoft Corporation, Google LLC, NVIDIA Corporation, Schrodinger, Atomwise, Recursion Pharmaceuticals, Exscientia, DeepMind (Alphabet), and various other regional and emerging biotechnology AI solution providers, among others.

Key Questions Answered in the Report-

• What is the current revenue generated by the AI in biotechnology market globally?
• At what rate is the global AI in biotechnology market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the global AI in biotechnology market?
• What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of technology, deployment, and end-use are expected to create major traction for the service providers in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global AI in biotechnology market?
• Who are the major players in the global AI in biotechnology market? What are their specific product offerings in this market?
• What are the recent strategic developments in the global AI in biotechnology market? What are the impacts of these strategic developments on the market?

Scope of the Report:

AI in Biotechnology Market Assessment -- by Technology

• Drug Discovery & Development
• Genomics & Gene Editing
• Precision Medicine
• Bioprocessing & Manufacturing
• Diagnostics & Imaging

AI in Biotechnology Market Assessment -- by Deployment

• Cloud-Based
• On-Premise

AI in Biotechnology Market Assessment -- by End-Use

• Pharmaceutical Companies
• Biotechnology Companies
• Academic Research Institutions
• Contract Research Organizations

AI in Biotechnology Market Assessment -- by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Singapore
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Scope
• 1.3. Research Methodology
• 1.4. Assumptions & Limitations

2. Executive Summary

3. Market Overview

• 3.1. Introduction
• 3.2. Market Dynamics
  • 3.2.1. Drivers
  • 3.2.2. Restraints
  • 3.2.3. Opportunities
  • 3.2.4. Challenges
• 3.3. Impact of Generative AI and Foundation Models on Biotechnology
• 3.4. Regulatory Landscape & Ethical Considerations
• 3.5. Porter's Five Forces Analysis

4. Global AI in Biotechnology Market, by Technology

• 4.1. Introduction
• 4.2. Drug Discovery & Development
  • 4.2.1. Target Identification & Validation
  • 4.2.2. Lead Generation & Optimization
  • 4.2.3. Preclinical Development
  • 4.2.4. Clinical Trial Design & Optimization
• 4.3. Genomics & Gene Editing
  • 4.3.1. Genome Sequencing & Analysis
  • 4.3.2. CRISPR & Gene Therapy Design
  • 4.3.3. Functional Genomics
• 4.4. Precision Medicine
  • 4.4.1. Patient Stratification & Biomarker Discovery
  • 4.4.2. Treatment Response Prediction
  • 4.4.3. Personalized Treatment Planning
• 4.5. Bioprocessing & Manufacturing
  • 4.5.1. Process Optimization
  • 4.5.2. Quality Control & Monitoring
  • 4.5.3. Yield Prediction & Enhancement
• 4.6. Diagnostics & Imaging
  • 4.6.1. Medical Imaging Analysis
  • 4.6.2. Digital Pathology
  • 4.6.3. Disease Detection & Screening
• 4.7. Others (Protein Engineering, Synthetic Biology, Agricultural Biotechnology)

5. Global AI in Biotechnology Market, by Deployment

• 5.1. Introduction
• 5.2. Cloud-based
• 5.3. On-premise
• 5.4. Hybrid

6. Global AI in Biotechnology Market, by End-use

• 6.1. Introduction
• 6.2. Pharmaceutical Companies
  • 6.2.1. Large Pharmaceutical Companies
  • 6.2.2. Small & Medium Pharmaceutical Companies
• 6.3. Biotechnology Companies
• 6.4. Research Institutes & Academic Centers
• 6.5. Hospitals & Diagnostic Centers
• 6.6. Contract Research Organizations (CROs)

7. Global AI in Biotechnology Market, by Region

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. U.S.
  • 7.2.2. Canada
• 7.3. Europe
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Switzerland
  • 7.3.5. Italy
  • 7.3.6. Spain
  • 7.3.7. Netherlands
  • 7.3.8. Rest of Europe
• 7.4. Asia-Pacific
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. India
  • 7.4.4. Singapore
  • 7.4.5. South Korea
  • 7.4.6. Australia
  • 7.4.7. Rest of Asia-Pacific
• 7.5. Latin America
  • 7.5.1. Brazil
  • 7.5.2. Mexico
  • 7.5.3. Argentina
  • 7.5.4. Rest of Latin America
• 7.6. Middle East & Africa
  • 7.6.1. Saudi Arabia
  • 7.6.2. UAE
  • 7.6.3. Israel
  • 7.6.4. South Africa
  • 7.6.5. Rest of Middle East & Africa

8. Competitive Landscape

• 8.1. Overview
• 8.2. Key Growth Strategies
• 8.3. Competitive Benchmarking
• 8.4. Competitive Dashboard
  • 8.4.1. Industry Leaders
  • 8.4.2. Market Differentiators
  • 8.4.3. Vanguards
  • 8.4.4. Emerging Companies
• 8.5. Market Ranking / Positioning Analysis of Key Players, 2025

9. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)

• 9.1. IBM Watson Health (IBM Corporation)
• 9.2. Google DeepMind (Alphabet Inc.)
• 9.3. Microsoft Corporation
• 9.4. NVIDIA Corporation
• 9.5. BenevolentAI
• 9.6. Exscientia plc
• 9.7. Recursion Pharmaceuticals, Inc.
• 9.8. Insilico Medicine
• 9.9. Atomwise, Inc.
• 9.10. Insitro
• 9.11. PathAI
• 9.12. Tempus AI, Inc.
• 9.13. SOPHiA GENETICS
• 9.14. Freenome Holdings, Inc.
• 9.15. Aidoc Medical Ltd.

10. Appendix

• 10.1. Questionnaire
• 10.2. Related Reports